Use of midodrine in heart failure: a review.
cardiac failure
congestive cardiac failure
heart failure
hypotension
midodrine
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
27
03
2023
accepted:
15
05
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
Heart failure is a global health concern, affecting millions of individuals worldwide. Midodrine, an alpha-1 receptor agonist, might be a potential treatment option for patients with heart failure and concurrent hypotension. This review provides a comprehensive summary of the existing literature on the use of midodrine in heart failure patients, focusing on its pharmacology, epidemiology, and public health impact. Guideline-directed medical therapy (GDMT) is essential in heart failure management, but hypotension may limit its initiation or up-titration. Studies have shown that midodrine can improve blood pressure, reduce the need for vasopressor support, and enable the prescription of GDMT in patients who are intolerant to it due to hypotension. However, there are concerns over increased all-cause mortality in some studies, small sample sizes, and nonrandomized study designs in others. Further research, including large-scale randomized controlled trials and long-term follow-up studies, is needed to better understand the risks and benefits of midodrine use in heart failure patients, particularly in relation to GDMT. Clinicians should consider the potential advantages of midodrine against the limited evidence and potential risks before incorporating it into their clinical practice for heart failure treatment.
Identifiants
pubmed: 37363594
doi: 10.1097/MS9.0000000000000922
pii: AMSU-D-23-00651
pmc: PMC10289700
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2808-2813Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
None.
Références
Crit Care Med. 2019 Aug;47(8):e648-e653
pubmed: 31107279
Circulation. 2018 Sep 25;138(13):e210-e271
pubmed: 29084733
Heart Fail Rev. 2016 Mar;21(2):199-211
pubmed: 26883434
N Engl J Med. 1997 Nov 6;337(19):1360-9
pubmed: 9358131
Am J Physiol Heart Circ Physiol. 2021 Feb 1;320(2):H725-H733
pubmed: 33275531
World J Cardiol. 2020 Aug 26;12(8):373-408
pubmed: 32879702
Arch Intern Med. 2004 Jul 12;164(13):1389-94
pubmed: 15249347
BMJ. 2000 Jan 15;320(7228):167-70
pubmed: 10634740
Am J Med Sci. 2009 Dec;338(6):470-3
pubmed: 19875951
Curr Heart Fail Rep. 2013 Dec;10(4):401-10
pubmed: 24078336
Nat Clin Pract Cardiovasc Med. 2008 Jul;5(7):375-86
pubmed: 18542106
Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
Compr Physiol. 2015 Dec 15;6(1):187-214
pubmed: 26756631
JACC Cardiovasc Imaging. 2011 Jan;4(1):98-108
pubmed: 21232712
SAGE Open Med Case Rep. 2022 May 18;10:2050313X221100400
pubmed: 35601610
Ann Med. 2005;37(2):74-85
pubmed: 16026115
Congest Heart Fail. 2009 May-Jun;15(3):108-11
pubmed: 19522958
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
J Cardiovasc Dev Dis. 2017 Feb 28;4(1):
pubmed: 29367535
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Nat Rev Cardiol. 2011 Oct 25;8(12):673-85
pubmed: 22027657
Eur J Case Rep Intern Med. 2022 Mar 18;9(3):003246
pubmed: 35402323
Circulation. 2006 Oct 10;114(15):1633-44
pubmed: 17030703
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Circ Heart Fail. 2012 Nov;5(6):819
pubmed: 23170021
Circ Heart Fail. 2012 Nov;5(6):720-6
pubmed: 22936826
Rev Esp Cardiol. 2004 Mar;57(3):250-9
pubmed: 15056429
Nat Rev Cardiol. 2014 Sep;11(9):507-15
pubmed: 24958077
Heart. 2004 Apr;90(4):464-70
pubmed: 15020532
Clin Cardiol. 2019 Dec;42(12):1155-1161
pubmed: 31524968
Methodist Debakey Cardiovasc J. 2020 Jan-Mar;16(1):22-26
pubmed: 32280414
Drugs. 1989 Nov;38(5):757-77
pubmed: 2480881
J Mol Cell Cardiol. 2011 Oct;51(4):518-28
pubmed: 21118696